Breaking Finance News

TherapeuticsMD TXMD (NYSE:TXMD) target price raised to $20.00, issued a report today by Stifel Nicolaus

Yesterday TherapeuticsMD TXMD (NYSE:TXMD) traded -3.76% lower at $4.31. The company’s 50-day moving average is $5.83 and its 200-day moving average is $5.56. The last stock close price is down 19.56% from the 200-day moving average, compared to the S&P 500 which has increased 0.02% over the same time. 846,705 shares of the stock were exchanged, down from an average trading volume of 2,556,020

TherapeuticsMD TXMD (NYSE:TXMD) had its target price raised to $20.00 by Stifel Nicolaus in a report released 05/25/2017. The new target price indicates a possible upside of 3.64% based on the company's last stock close price.

Previously on 5/11/2017, Cantor Fitzgerald reported about TherapeuticsMD TXMD (NYSE:TXMD) raised the target price from $0.00 to $33.00. At the time, this indicated a possible upside of 6.67%.

See Chart Below

TherapeuticsMD TXMD (NYSE:TXMD)

TherapeuticsMD TXMD has a 52 week low of $3.50 and a 52 week high of $8.30 The company’s market cap is currently $0.

In addition to Stifel Nicolaus reporting its target price, a total of 5 firms have issued a report on the stock. The consensus target price is $19.30 with 3 firms rating the stock a strong buy, 2 firms rating the stock a buy, 0 firms rating the stock a hold, 0 firms rating the stock a underperform, and finally 0 firms rating the stock a sell.

About TherapeuticsMD TXMD (NYSE:TXMD)

TherapeuticsMD, Inc. is a women's healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort. With its SYMBODA technology, it is developing hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through dosage forms and administration routes. Its product line includes vitaTrue, vitaPearl, vitaMedMD Plus, vitaMedMD One Prenatal Multivitamin, vitaMedMD Plus Rx Prenatal Multivitamin, vitaMedMD One Rx Prenatal Multivitamin, vitaMedMD Iron 21/7, vitaMedMD Vitamin D3 50,000 IU, BocaGreenMD Prena1 Pearl and BocaGreenMD Prena1 Chew.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *